^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Testicular Cancer |
| Drug: | BNT211 (CLDN6-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer
Published date:
06/23/2022
Excerpt:
BioNTech SE...today announced that that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to BioNTech’s fully owned product candidate BNT211 for the third- or later-line treatment of testicular germ cell tumors.
